XML 38 R29.htm IDEA: XBRL DOCUMENT v3.7.0.1
Description of Business and Significant Accounting Policies - Additional Information (Detail)
 1 Months Ended 3 Months Ended 12 Months Ended
Apr. 18, 2017
USD ($)
Mar. 01, 2017
shares
Nov. 09, 2016
USD ($)
Jan. 31, 2017
USD ($)
Mar. 31, 2017
USD ($)
Distributor
$ / shares
shares
Mar. 31, 2016
USD ($)
Dec. 31, 2016
USD ($)
Distributor
shares
Sep. 30, 2016
shares
Dec. 31, 2015
USD ($)
Sep. 23, 2014
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                    
Net revenue from collaboration         $ 63,000          
Accumulated deficit         (2,753,889,000)   $ (2,737,565,000)      
Cash and cash equivalents         $ 47,978,000 $ 27,653,000 $ 22,895,000   $ 59,074,000  
Stock market bidding requirements, description         On September 14, 2016, the Company received notice from the Listing Qualifications Department of the NASDAQ Stock Market indicating that in the previous 30 consecutive business days, the bid price for the common stock closed below the minimum of $1.00 per share required for continued inclusion on the NASDAQ Global Market.          
Minimum closing bid requirement, price per share | $ / shares         $ 1.00          
Stock split of common stock   0.2                
Common stock, shares authorized | shares   140,000,000     140,000,000   140,000,000 700,000,000    
Reverse stock split, description         The Company’s board of directors approved a reverse stock split ratio of 1-for-5. On March 1, 2017, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of the Company’s Amended and Restated Certificate of Incorporation to effect the 1-for-5 reverse stock split of the Company’s outstanding common stock and to reduce the authorized number of shares of the Company’s common stock from 700,000,000 to 140,000,000 shares. The Company’s common stock began trading on the NASDAQ Global Market on a split-adjusted basis when the market opened on March 3, 2017. As a result, all common stock share amounts included in these condensed consolidated financial statements have been retroactively reduced by a factor of five, and all common stock per share amounts have been increased by a factor of five, with the exception of the Company’s common stock par value.          
Deferred revenue         $ 1,844,000   $ 3,419,000      
Net revenue - commercial product sales         $ 1,196,000          
Number of wholesale distributors | Distributor         3          
Percentage of product shipments to wholesale distributors         93.00%          
Product sales         $ 3,009,000          
Cash discount as incentive for prompt payment         2.00%          
Deferred revenue from sale of raw insulin         $ 0   $ 1,800,000      
Number of wholesale distributors accounted for gross accounts receivable | Distributor         3   3      
Allowance for doubtful accounts         $ 0   $ 0      
Percentage of accounts receivable from major wholesale distributors         92.00%   95.00%      
Loss on purchase commitments, number of contracts recognized         0   0      
License and Collaboration Agreement with Sanofi                    
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                    
Gain on extinguishment of debt     $ 500,000              
Senior notes, effective interest rate                   8.50%
Third party logistics                    
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                    
Deferred revenue         $ 1,800,000   $ 1,600,000      
Insulin Put                    
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                    
Net revenue from collaboration             10,200,000      
AFREZZA product sales                    
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                    
Product sales revenue gross to net adjustments         $ 400,000 0        
Product sales revenue gross to net adjustments percentage         27.00%          
Product sales           $ 0        
Less portion of commitment asset                    
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                    
Cash repayment of senior notes under exchange agreement         $ 4,000,000          
Conversion of notes to common shares, value         $ 1,000,000          
Minimum | AFREZZA product sales                    
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                    
Sales return right following product expiration in months         6 months          
Maximum | AFREZZA product sales                    
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                    
Sales return right following product expiration in months         12 months          
Senior convertible notes due December 31, 2019                    
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                    
Conversion of notes to common shares, value         $ 5,000,000          
Allowance for Sales Returns                    
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                    
Allowance for returns         300,000   0      
Principal stockholder | Loan Arrangement                    
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                    
Amount available for future borrowings         30,100,000   30,100,000      
Principal stockholder | Senior convertible notes due December 31, 2019 | Loan Arrangement                    
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                    
Amount available for future borrowings         30,100,000          
Sanofi-Aventis Deutschland GmbH | License and Collaboration Agreement with Sanofi                    
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                    
Net revenue from collaboration         172,000,000          
Up-front fee         150,000,000          
Sanofi-Aventis Deutschland GmbH | Insulin Put | License and Collaboration Agreement with Sanofi                    
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                    
Net revenue from collaboration         19,400,000          
Sanofi-Aventis Deutschland GmbH | AFREZZA product sales | License and Collaboration Agreement with Sanofi                    
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                    
Net revenue from collaboration         $ 17,500,000          
Sanofi-Aventis Deutschland GmbH | Put Option                    
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                    
Payment for insulin put option       $ 30,600,000     $ 30,600,000      
Aventisub LLC                    
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                    
Outstanding loan balance forgive     $ 72,000,000              
Deerfield | Senior convertible notes due December 31, 2019                    
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                    
Senior notes, effective interest rate         9.75%          
Deerfield | Senior convertible notes due December 31, 2019 | Less portion of commitment asset                    
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                    
Senior notes, effective interest rate         8.75%          
Deerfield | Senior convertible notes due December 31, 2019 | Less portion of commitment asset | Subsequent Event                    
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                    
Cash repayment of senior notes under exchange agreement $ 4,000,000                  
Conversion of notes to common shares, value 1,000,000                  
Deerfield | Senior convertible notes due December 31, 2019 | Tranche 1 Notes | Subsequent Event                    
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                    
Conversion of notes to common shares, value $ 5,000,000                  
Deerfield | Senior convertible notes due December 31, 2019 | Minimum | Less portion of commitment asset                    
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                    
Available amount of credit facility under covenant restrictions         $ 25,000,000